WO2005089749A2 - Utilisation du metronidazole pour le traitement d’ un desordre de la vascularisaton cutanee - Google Patents
Utilisation du metronidazole pour le traitement d’ un desordre de la vascularisaton cutanee Download PDFInfo
- Publication number
- WO2005089749A2 WO2005089749A2 PCT/FR2005/000369 FR2005000369W WO2005089749A2 WO 2005089749 A2 WO2005089749 A2 WO 2005089749A2 FR 2005000369 W FR2005000369 W FR 2005000369W WO 2005089749 A2 WO2005089749 A2 WO 2005089749A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- receptor
- use according
- metronidazole
- composition
- chosen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the present invention relates to the field of the treatment of disorders of the skin vascularization, and more particularly the treatment of disorders of the skin vascularization in rosacea.
- the invention aims to provide new pharmaceutical compositions, more particularly dermatological compositions, useful for the treatment of disorders of the cutaneous vascularization, and more particularly the treatment of disorders of the cutaneous vascularization in rosacea and comprising as active agent metronidazole .
- Rosacea is a common chronic and progressive inflammatory dermatosis linked to vascular relaxation. It mainly affects the central part of the face and is characterized by reddening of the face or hot flashes, facial er, papules, pustules, and telangiectasia. In severe cases, especially in humans, the soft tissue in the nose can swell and produce a bulbous swelling called rhinophyma.
- Rosacea usually occurs between the ages of 25 and 70, and is much more common in fair skinned people. It affects more particularly women, although this condition is generally more severe in men. Rosacea is chronic and persists for years with periods of exacerbation and remission.
- Rosacea was originally called "acne rosacea” because its papules (slight raised skin) and inflammatory pustules (scabs of pus) are very similar to those of acne vulgaris.
- the etiology of which is based on both abnormal keratinization, increased sebum production and bacterial inflammation, inflammation of rosacea is vascular in nature and poorly understood.
- the result of this facial vascular anomaly is a permanent edema of the dermis which could accompany increased colonization by Demodex folliculorum, a mite that is usually found in the follicles of the face.
- stage 2 erythematato-telangiectatic (around 30 years).
- the malar areas are diffusely red.
- the chin and the middle part of the forehead can be affected.
- stage 4 of rhinophyma (around 50 years or later). This late phase mainly affects men, unlike the other stages.
- the nose is increased by volume, diffusely red and the follicular orifices are dilated.
- the skin gradually thickens.
- Minor forms of rosacea can be treated with active ingredients such as anti-seborrheics and anti-infectives, for example benzoyl peroxide, retinoic acid.
- active ingredients such as anti-seborrheics and anti-infectives, for example benzoyl peroxide, retinoic acid.
- active ingredients such as anti-seborrheics and anti-infectives, for example benzoyl peroxide, retinoic acid.
- active ingredients such as anti-seborrheics and anti-infectives, for example benzoyl peroxide, retinoic acid.
- benzoyl peroxide for example benzoyl peroxide, retinoic acid.
- cyclins As for the most diffuse forms of the disease, they respond well to general antibiotic therapy with cyclins. However, these treatments have unpleasant side effects for the patient, such as irritation or intolerance.
- the work of the Applicant has made it possible to demonstrate the interaction of metronidazole with the receptors chosen from the group comprising beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor, the galanin in the treatment of rosacea.
- Beta-adrenergic receptors are involved in the regulation of various physiological functions, such as metabolic activity, cardiac activity, respiration, central nervous system activity, blood pressure and vascular tone.
- the 5-HT2 receptors the 5-HT5 receptors belong to the family of serotonin (5-HT) receptors. All 5-HT receptors are coupled to G proteins, except 5HT3 which is an ion channel. Activation of 5-HT2 receptors stimulates the activity of phospholipase C.
- the transduction system of 5-HT5 receptors is positively associated with adenylate cyclase.
- the AT1 receptor is involved in the regulation of vasoconstriction by angiotensin II.
- angiotensin II increases the tone of the subcutaneous arteries.
- Galanine is a peptide of 29 amino acids found in the central nervous system. According to certain studies, galanine has a role in the modulation of the cutaneous vascular reaction and in inflammation (Pincelli, 1990, Br J dermatol, vol. 122, pages 745-750).
- Metronidazole or (methyl-2-nitro-5-imidazolyl) -2-ethanol, is known in the prior art for its antibacterial, antiparasitic and antiprotozoal properties. It exerts a selective toxicity with respect to anaerobic microorganisms as well as hypoxic cells. At the level of the latter, metronidazole is reduced to derivatives capable of altering the DNA structure of these cells.
- the work of the Applicant has made it possible to demonstrate the involvement of beta-adrenergic receptors, of the AT1 receptor, of the 5-HT2 receptor, of the 5-HT5 receptor, and of the galanin receptor in disorders of the cutaneous vascularization.
- the Applicant has now demonstrated the advantageous properties of metronidazole on disorders of the skin vascularization and more particularly on disorders of the skin vascularization in rosacea.
- metronidazole resulted in an interaction with beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor, and the galanin receptor. More specifically, it has been found that the use of metronidazole inhibits the binding of natural ligands to these receptors.
- the invention aims to offer a new method of treatment of a cutaneous vascular disorder consisting in administering to a subject suffering from disorders of the cutaneous vascularization, an effective amount of metronidazole, in which metronidazole is capable of interact with at least one receptor chosen from the group comprising beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor, and the galanin receptor.
- the invention relates more particularly to the use of metronidazole for the preparation of a pharmaceutical composition, intended for the treatment of a disorder of the cutaneous vascularization. More particularly, the invention relates to the use of metronidazole for the preparation of a pharmaceutical composition intended for the treatment of a cutaneous vascular disorder, involving at least one receptor chosen from the group comprising beta-adrenergic receptors, the AT1 receptor , the 5-HT2 receptor, the 5-HT5 receptor, and the galanin receptor.
- the invention also relates to the use of metronidazole for the preparation of a pharmaceutical composition intended for the treatment of a cutaneous vascular disorder, involving at least two receptors chosen from the group comprising beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, 5-HT5 receptor, and the galanin receptor.
- the invention also relates to the use of metronidazole for the preparation of a pharmaceutical composition intended for the treatment of a cutaneous vascular disorder, involving at least three receptors chosen from the group comprising beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, 5-HT5 receptor, and the galanin receptor.
- the invention also relates to the use of metronidazole for the preparation of a pharmaceutical composition intended for the treatment of a cutaneous vascular disorder, involving at least four receptors chosen from the group comprising beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, 5-HT5 receptor, and the galanin receptor.
- the invention also relates to the use of metronidazole for the preparation of a pharmaceutical composition intended for the treatment of a cutaneous vascular disorder, involving at least five receptors chosen from the group comprising beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, 5-HT5 receptor, and the galanin receptor.
- the invention relates to the use of metronidazole for the preparation of a pharmaceutical composition intended for the treatment of a cutaneous vascular disorder, said vascular disorder being a component of rosacea and the metronidazole of said composition being capable of '' interact with at least one receptor selected from the group comprising beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor, and the galanin receptor.
- the invention also relates to the use of metronidazole for the preparation of a pharmaceutical composition as defined above, in which metronidazole is capable of interacting with at least two receptors chosen from the group comprising beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor, and the galanin receptor.
- the invention also relates to the use of metronidazole for the preparation of a pharmaceutical composition as defined above, in which metronidazole is capable of interacting with at least three receptors chosen from the group comprising beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor, and the galanin receptor.
- the invention also relates to the use of metronidazole for the preparation of a pharmaceutical composition as defined above, in which metronidazole is capable of interacting with at least four receptors chosen from the group comprising beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor, and the galanin receptor.
- the invention also relates to the use of metronidazole for the preparation of a pharmaceutical composition defined above, in which metronidazole is capable of interacting with at least five receptors chosen from the group comprising beta-adrenergic receptors, the receptor AT1, the 5-HT2 receptor, the 5-HT5 receptor, and the galanin receptor.
- the invention relates to the use of metronidazole for the preparation of a pharmaceutical composition in which metronidazole inhibits the binding of at least one natural ligand to its receptor, said receptor being chosen from the group comprising receptors beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor, and the galanin receptor.
- composition object of the present invention is a dermatological composition, for topical administration on the skin.
- treatment of disorders of the skin vascularization is meant according to the present invention, the treatment and / or prevention of such a disorder.
- rosacea treatment is understood to mean, according to the present invention, the treatment and / or prevention of rosacea, in one or more of the stages described above.
- the composition is intended for the treatment of the first stage of rosacea.
- the composition is intended for the treatment of the second stage of rosacea.
- the composition is intended for the treatment of the third stage of rosacea.
- the composition is intended for the treatment of the fourth stage of rosacea.
- the composition contains 0.0001 to 20% by weight of metronidazole, preferably from 0.1 to 2%, and more preferably of the order of 0.75 to 1% of expressed metronidazole as a percentage by weight relative to the total weight of the composition.
- the present invention relates, in addition to the use of metronidazole, the use of derivatives thereof.
- derivatives means compounds which are distinguished from metronidazole, by substitution, addition or deletion of one or more chemical groups and having substantially the same activity.
- compositions of the invention comprise, in addition to metronidazole, at least one other therapeutic agent capable of increasing the effectiveness of the treatment.
- at least one other therapeutic agent capable of increasing the effectiveness of the treatment.
- antibiotics antibacterials, antivirals, antiparasitics, antifungals, anesthetics, analgesics, antiallergics, retinoids, anti-free radicals, antipruritics, keratolytics, antiseborrhoeics, antihistamines, sulfides, immunosuppressive or antiproliferative products.
- compositions of the invention may also comprise any additive usually used in the pharmaceutical, dermatological field, compatible with metronidazole. Mention may in particular be made of sequestrants, antioxidants, sun filters, preservatives, for example DL-alpha-tocopherol, fillers, electrolytes, humectants, dyes, bases or common acids, mineral or organic, fragrances, essential oils, cosmetic active ingredients, moisturizers, vitamins, essential fatty acids, sphingolipids, self-tanning compounds such as DHA, soothing and protective agents for the skin such as allantoin, penetrating agents , gelling agents.
- sequestrants for example DL-alpha-tocopherol
- fillers electrolytes, humectants, dyes, bases or common acids, mineral or organic, fragrances, essential oils, cosmetic active ingredients, moisturizers, vitamins, essential fatty acids, sphingolipids, self-tanning compounds such as DHA, soothing and protective agents for the skin such as allantoin, pe
- additives can be present in the composition in an amount of 0 to 20% by weight relative to the total weight of the composition.
- sequestering agents examples include ethylenediamine tetracetic acid (EDTA), as well as its derivatives or its salts, dihydroxyethylglycine, citric acid, tartaric acid, or mixtures thereof.
- EDTA ethylenediamine tetracetic acid
- preservatives examples include benzalkonium chloride, phenoxyethanol, benzyl alcohol, diazolidinylurea, parabens, or mixtures thereof.
- humectants examples include glycerin and sorbitol.
- compositions of the invention may contain one or more penetrating agents in preferential concentrations ranging from 0 to 20% and more preferably ranging from 0.6 to 3% by weight relative to the total weight of the composition.
- penetrating agents use is preferably made, without this list being limiting, of compounds such as propylene glycol, dipropylene glycol, propylene glycol dipelargonate, lauroglycol, ethoxydiglycol.
- the compositions according to the invention may also contain one or more surfactants in preferential concentrations ranging from 0 to 10% and more preferably ranging from 0.1 to 2%.
- compositions of the present invention may be in all the galenical forms normally used for topical application, in particular in the form of aqueous, hydroalcoholic or oily solutions, of lotion-type dispersions, of aqueous, anhydrous or lipophilic gels, of emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersion of a fatty phase in an aqueous phase (O / W) or vice versa (W / O), or of suspensions or emulsions of soft, semi-liquid or solid consistency of cream, gel or ointment type or microemulsions, micro-capsules, micro-particles or vesicular dispersions of ionic and / or non-ionic type.
- the creams can be formulated from a mixture of mineral oil, or a mixture of beeswax and water which instantly emulsifies, in which metronidazole is added, dissolved in a small amount of oil such as almond oil.
- Ointments can be formulated by mixing a solution of metronidazole in an oil such as almond oil in chiauffered paraffin, then allowing the mixture to cool.
- compositions according to the invention mention may be made of these islands comprising an active phase containing (expressed as a percentage by weight): - 0 to 90%, preferably 5 to 25%, in particular 10 to 20%, of water;
- aqueous phase comprising a gelling agent and water.
- the aqueous phase of a composition according to the invention in the form of an emulsion may comprise water, floral water such as blueberry water, or natural thermal or mineral water, for example chosen from Vittel water, Vichy basin water, Uriage water, Roche Pos ay water, Bourboule water, Enghien-les-Bains water, water of Saint Gervais-les-Bains, the water of Néris- les-Bains, water from Allevard-les-Bains, water from Digne, water from Maizines, water from Neyrac-les-Bains, water from Lons-le-Saunier, Eaux Bonnes , Rochefort water, Saint Christau water, Fumades water and Tercis-les-Bains water, Avene water or Aix les Bains water.
- Said aqueous phase may be present at a content of between 10 and 90% by weight relative to the total weight of the composition, preferably between 20 and 80% by weight.
- gelling agents of the polyacrylamide family such as the Sodium acryloyldimethyltaurate copolymer / isohexadecane / polysorbate 80 mixture sold under the name Simulgel 600 by the company Seppic, the polyacrylamide / isoparaffin C13-14 / laureth-7 like, for example, that sold under the name of Sepigel 305 by the company Seppic, the family of acrylic polymers coupled to hydrophobic chains such as the PEG-150 / decyl / SMDI copolymer sold under the name of Aculyn 44 ( polycondensate comprising at least as elements, a polyethylene glycol with 150 or 180 moles of ethylene oxide, decyl alcohol and methylene bis (4-cyclohexylisocyanate) (SMDI), at 35% by weight in a mixture of propylene glycol ( 39%) and water (26%)), the family of modified starches such as modified potato starch sold under the name Structure
- the preferred gelling agents come from the family of polyacrylamides such as Simulgel 600 or Sepigel 305 or their mixtures.
- the gelling agent as described above can be used at preferential concentrations ranging from 0.1 to 15% and, more preferably, ranging from 0.5 to 5%.
- the gels can preferably be prepared by dispersing or dissolving metronidazole in an appropriate ratio, in a gel of carbomer, poloxamer or cellulosic type.
- the AT1 receptor binding test was carried out according to the method described by
- the 5-HT 5A receptor binding test was carried out according to the method described by Ress et al, 1994, FEBS Lett, vol. 355, pages 242-246.
- the 5-HT ⁇ receptor binding test was carried out according to the method described by
- the galanin receptor binding test was carried out according to the method described by Sullivan et al, 1997, Biochem Biophys Res Comm, vol. 233, pages 823-828.
- the binding of metronidazole to each receptor was determined by competitive experiments.
- the receptor, recombinant human protein was incubated according to the times indicated in Table 1 below, with a single concentration of specific labeled ligand, in the presence of metronidazole at 10 ⁇ M. Bound radioactivity was measured by scintillation counting.
- the specific binding of the ligand to the receptor is defined as the difference between the total binding and the non-specific binding determined in the presence of an excess of unlabeled ligand.
- Metronidazole interacts and therefore inhibits binding to beta adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor, and the galanin receptor.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006553617A JP2007523132A (ja) | 2004-02-20 | 2005-02-17 | 皮膚の血管新生疾患を治療するための医薬組成物の調製における、メトロニダゾールの使用 |
CA002554637A CA2554637A1 (fr) | 2004-02-20 | 2005-02-17 | Utilisation du metronidazole pour le traitement d` un desordre de la vascularisaton cutanee |
AU2005224122A AU2005224122A1 (en) | 2004-02-20 | 2005-02-17 | Use of metronidazole for preparing a pharmaceutical composition for treating a cutaneous vascularisation disorder |
BRPI0506557-7A BRPI0506557A (pt) | 2004-02-20 | 2005-02-17 | uso do metronidazol para a preparação de uma composição farmacêutica |
EP05729333A EP1732542A2 (fr) | 2004-02-20 | 2005-02-17 | Utilisation du metronidazole pour le traitement d'un desordre de la vascularisaton cutanee |
US10/590,074 US20070238772A1 (en) | 2004-02-20 | 2005-02-17 | Use of Metronidazole for Preparing a Pharmaceutical Composition for Treating a Cutaneous Vascularisation Disorder |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0401720A FR2866568B1 (fr) | 2004-02-20 | 2004-02-20 | Utilisation du metronidazole pour la preparation d'une composition pharmaceutique destinee a traiter un desordre de la vascularisation cutanee |
FR04/01720 | 2004-02-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005089749A2 true WO2005089749A2 (fr) | 2005-09-29 |
WO2005089749A3 WO2005089749A3 (fr) | 2006-05-04 |
Family
ID=34833945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2005/000369 WO2005089749A2 (fr) | 2004-02-20 | 2005-02-17 | Utilisation du metronidazole pour le traitement d’ un desordre de la vascularisaton cutanee |
Country Status (11)
Country | Link |
---|---|
US (1) | US20070238772A1 (fr) |
EP (1) | EP1732542A2 (fr) |
JP (1) | JP2007523132A (fr) |
KR (1) | KR20060124708A (fr) |
CN (1) | CN1921850A (fr) |
AU (1) | AU2005224122A1 (fr) |
BR (1) | BRPI0506557A (fr) |
CA (1) | CA2554637A1 (fr) |
FR (1) | FR2866568B1 (fr) |
RU (1) | RU2006133535A (fr) |
WO (1) | WO2005089749A2 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010085753A1 (fr) * | 2009-01-23 | 2010-07-29 | Jr Chem, Llc | Traitements pour l'acné rosacée et trousses médicales pour les mettre en pratique |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4837378A (en) * | 1986-01-15 | 1989-06-06 | Curatek Pharmaceuticals, Inc. | Topical metronidazole formulations and therapeutic uses thereof |
CA2161737A1 (fr) * | 1995-10-30 | 1997-05-01 | Richard J. Mackay | Gel de metronidazole |
WO1998027960A2 (fr) * | 1996-12-20 | 1998-07-02 | Bioglan Ireland (R & D) Limited | Composition gelifiee a base de nitro-imidazole |
WO2004112780A1 (fr) * | 2003-06-18 | 2004-12-29 | Galderma S.A. | Composition pharmaceutique topique de teinte verte a base de metronidazole |
-
2004
- 2004-02-20 FR FR0401720A patent/FR2866568B1/fr not_active Expired - Fee Related
-
2005
- 2005-02-17 RU RU2006133535/15A patent/RU2006133535A/ru unknown
- 2005-02-17 JP JP2006553617A patent/JP2007523132A/ja active Pending
- 2005-02-17 US US10/590,074 patent/US20070238772A1/en not_active Abandoned
- 2005-02-17 CA CA002554637A patent/CA2554637A1/fr not_active Abandoned
- 2005-02-17 CN CNA2005800055709A patent/CN1921850A/zh active Pending
- 2005-02-17 BR BRPI0506557-7A patent/BRPI0506557A/pt not_active Application Discontinuation
- 2005-02-17 KR KR1020067016589A patent/KR20060124708A/ko not_active Application Discontinuation
- 2005-02-17 EP EP05729333A patent/EP1732542A2/fr not_active Withdrawn
- 2005-02-17 WO PCT/FR2005/000369 patent/WO2005089749A2/fr not_active Application Discontinuation
- 2005-02-17 AU AU2005224122A patent/AU2005224122A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4837378A (en) * | 1986-01-15 | 1989-06-06 | Curatek Pharmaceuticals, Inc. | Topical metronidazole formulations and therapeutic uses thereof |
CA2161737A1 (fr) * | 1995-10-30 | 1997-05-01 | Richard J. Mackay | Gel de metronidazole |
WO1998027960A2 (fr) * | 1996-12-20 | 1998-07-02 | Bioglan Ireland (R & D) Limited | Composition gelifiee a base de nitro-imidazole |
WO2004112780A1 (fr) * | 2003-06-18 | 2004-12-29 | Galderma S.A. | Composition pharmaceutique topique de teinte verte a base de metronidazole |
Non-Patent Citations (6)
Title |
---|
BLOUNT B W ET AL: "Rosacea: A common, yet commonly overlooked, condition" AMERICAN FAMILY PHYSICIAN 01 AUG 2002 UNITED STATES, vol. 66, no. 3, 1 août 2002 (2002-08-01), pages 435-440+442, XP008036105 ISSN: 0002-838X * |
COHEN A F ET AL: "Diagnosis and treatment of rosacea" JOURNAL OF THE AMERICAN BOARD OF FAMILY PRACTICE 2002 UNITED STATES, vol. 15, no. 3, 2002, pages 214-217, XP008036097 ISSN: 0893-8652 * |
EGAN C A ET AL: "Rosacea induced by beclomethasone dipropionate nasal spray" INTERNATIONAL JOURNAL OF DERMATOLOGY 1999 UNITED KINGDOM, vol. 38, no. 2, 1999, pages 133-134, XP008036086 ISSN: 0011-9059 * |
MADDIN S: "A COMPARISON OF TOPICAL AZELAIC ACID 20% CREAM AND TOPICAL METRONIDAZOLE 0.75% CREAM IN THE TREATMENT OF PATIENTS WITH PAPULOPUSTULAR ROSACEA" JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, C.V. MOSBY, ST. LOUIS, MO, US, vol. 40, no. 6, PART 1, juin 1999 (1999-06), pages 961-965, XP008016063 ISSN: 0190-9622 * |
MOULIN G ET AL: "Rhinophyma" ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 1991 FRANCE, vol. 118, no. 4, 1991, pages 319-322, XP008036089 ISSN: 0151-9638 * |
ROHRICH R J ET AL: "Rhinophyma: Review and update" PLASTIC AND RECONSTRUCTIVE SURGERY 01 SEP 2002 UNITED STATES, vol. 110, no. 3, 1 septembre 2002 (2002-09-01), pages 860-870, XP008036088 ISSN: 0032-1052 * |
Also Published As
Publication number | Publication date |
---|---|
KR20060124708A (ko) | 2006-12-05 |
EP1732542A2 (fr) | 2006-12-20 |
US20070238772A1 (en) | 2007-10-11 |
WO2005089749A3 (fr) | 2006-05-04 |
CN1921850A (zh) | 2007-02-28 |
JP2007523132A (ja) | 2007-08-16 |
FR2866568A1 (fr) | 2005-08-26 |
AU2005224122A1 (en) | 2005-09-29 |
CA2554637A1 (fr) | 2005-09-29 |
FR2866568B1 (fr) | 2007-08-24 |
RU2006133535A (ru) | 2008-03-27 |
BRPI0506557A (pt) | 2007-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1898933A1 (fr) | Composition a base d une avermectine et de peroxyde de benzoyle notamment pour le traitement de la rosacee | |
CA2154730C (fr) | Nouvelles compositions a base d'un melange synergetique entre au moins un ligand specifique des rxrs et au moins un ligand specifique de rar-.alpha., et leurs utilisations | |
EP1722855A1 (fr) | Utilisation d'un compose antagoniste d'au moins un recepteur choisi dans le groupe comprenant les recepteurs beta-adrenergiques, le recepteur at1, 5-ht5 et de la galanine, pour la preparation d'une composition pharmaceutique destinee a traiter la rosacee | |
WO2006032759A1 (fr) | Utilisation du metronidazole en combinaison avec de l'acide azelaique pour le traitement de la rosacee | |
WO2005089750A2 (fr) | Utilisation du metronidazole pour le traitement des pathologies liees au recepteur de type b de l’interleukine 8 et/ou recepteur de type 1 de pacap | |
WO2005079770A2 (fr) | Utilisation d'un compose modulateur d'au moins un recepteur choisi parmi le recepteur de type b de l'il 8 et de type 1 de pacap pour la preparation d'une composition pharmaceutique pour traiter la rosacee | |
EP1732542A2 (fr) | Utilisation du metronidazole pour le traitement d'un desordre de la vascularisaton cutanee | |
EP1686975A1 (fr) | UTILISATION DU FEPRADINOL POUR LA PREPARATION D’UNE COMPOSITION PHARMACEUTIQUE POUR LE TRAITEMENT DE LA ROSACEE | |
EP1686978B1 (fr) | Utilisation de l'idrocilamide pour la preparation d'une composition pharmaceutique pour le traitement de la rosacee | |
WO2005089751A2 (fr) | Utilisation du metronidazole pour le traitement d’une inflammation cutanee | |
EP1722774A1 (fr) | Utilisation d'un compose modifiant la secretion de l'interleukine 5, de l'interleukine 6 et/ou de l'interleukine 10 pour la preparation d'une composition pharmaceutique destinee a traiter la rosacee | |
EP1686991A1 (fr) | Utilisation du piketoprofen pour la preparation d'une compos ition pharmaceutique pour le traitement de la rosacee | |
FR2899475A1 (fr) | Composition pharmaceutique pour le traitement de la rosacee | |
MXPA06009315A (es) | Uso de metronidazol para el tratamiento de un trastorno de la vascularizacion cutanea |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005729333 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2554637 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200606665 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005224122 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/009315 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006553617 Country of ref document: JP Ref document number: 1020067016589 Country of ref document: KR Ref document number: 4753/DELNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580005570.9 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
ENP | Entry into the national phase |
Ref document number: 2005224122 Country of ref document: AU Date of ref document: 20050217 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005224122 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006133535 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067016589 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2005729333 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10590074 Country of ref document: US Ref document number: 2007238772 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0506557 Country of ref document: BR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2005729333 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10590074 Country of ref document: US |